Timing of captopril administration determines radiation protection or radiation sensitization in a murine model of total body irradiation

Experimental Hematology

Volumn 38, Issue 4, 2010, Pages 270-281

  Davis, Thomas A ^a   Landauer, Michael R ^b   Mog, Steven R ^b   Barshishat Kupper, Michal ^b   Zins, Stephen R ^a   Amare, Mihret F ^a   Day, Regina M ^b  

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; COBALT 60;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CELL; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL LINEAGE; CELL POPULATION; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RADIATION PROTECTION; RADIOSENSITIZATION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; WHOLE BODY RADIATION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CAPTOPRIL; FEMALE; HEMATOPOIETIC STEM CELLS; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; RADIATION PROTECTION; TIME FACTORS; WHOLE-BODY IRRADIATION;

MURINAE; MUS;

EID: 77950791504     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2010.01.004     Document Type: Article

References (46)

1. Meder J., Michalowski A. Changes in cellularity and/or weight of mouse hemopoietic tissues as a measure of acute radiation effects. Arch Immunol Ther Exp 1980, 28:9-18.
2. Storb R. Allogeneic hematopoietic stem cell transplantation-yesterday, today, and tomorrow. Exp Hematol 2003, 31:1-10.
3. Wagemaker G. Heterogeneity of radiation sensitivity of hemopoietic stem cell subsets. Stem Cells 1995, 13(SUPPL 1):257-260.
4. Mouthon M.A., Van der Meeren A., Vandamme M., Squiban C., Gaugler M.H. Thrombopoietin protects mice from mortality and myelosuppression following high-dose irradiation: importance of time scheduling. Can J Physiol Pharmacol 2002, 80:717-721.
5. Tamulevicius P., Wang M., Iliakis G. Homology-directed repair is required for the development of radioresistance during S phase: interplay between double-strand break repair and checkpoint response. Radiat Res 2007, 167:1-11.
6. Davis T.A., Mungunsukh O., Zins S., Day R.M., Landauer M.R. Genistein induces radioprotection by hematopoietic stem cell quiescence. Int J Radiat Biol 2008, 84:713-726.
7. Greenberger J.S., Epperly M. Bone marrow-derived stem cells and radiation response. Semin Radiat Oncol 2009, 19:133-139.
8. Metcalf D. Hematopoietic cytokines. Blood 2008, 111:485-491.
9. Herodin F., Drouet M. Cytokine-based treatment of accidentally irradiated victims and new approaches. Exp Hematol 2005, 33:1071-1080.
10. Stroth U., Unger T. The renin-angiotensin system and its receptors. J Cardiovasc Pharmacol 1999, 33(SUPPL 1):S21-S28. discussion S41-S23.
11. Rodgers K., Xiong S., Steer R., DiZerega G. Effect of angiotensin II on hematopoietic progenitor cell proliferation. Stem Cells 2000, 18:287-294.
12. Zambidis E.T., Park T.S., Yu W., et al. Expression of angiotensin-converting enzyme (CD143) identifies and regulates primitive hemangioblasts derived from human pluripotent stem cells. Blood 2008, 112:3601-3614.
13. Bahlmann F.H., de Groot K., Mueller O., Hertel B., Haller H., Fliser D. Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension 2005, 45:526-529.
14. Chisi J.E., Wdzieczak-Bakala J., Thierry J., Briscoe C.V., Riches A.C. Captopril inhibits the proliferation of hematopoietic stem and progenitor cells in murine long-term bone marrow cultures. Stem Cells 1999, 17:339-344.
15. Chisi J.E., Briscoe C.V., Ezan E., Genet R., Riches A.C., Wdzieczak-Bakala J. Captopril inhibits in vitro and in vivo the proliferation of primitive haematopoietic cells induced into cell cycle by cytotoxic drug administration or irradiation but has no effect on myeloid leukaemia cell proliferation. Br J Haematol 2000, 109:563-570.
16. Rousseau-Plasse A., Wdzieczak-Bakala J., Lenfant M., et al. Lisinopril, an angiotensin I-converting enzyme inhibitor, prevents entry of murine hematopoietic stem cells into the cell cycle after irradiation in vivo. Exp Hematol 1998, 26:1074-1079.
17. Ellefson D.D., diZerega G.S., Espinoza T., Roda N., Maldonado S., Rodgers K.E. Synergistic effects of co-administration of angiotensin 1-7 and Neupogen on hematopoietic recovery in mice. Cancer Chemother Pharmacol 2004, 53:15-24.
18. Rodgers K.E., Xiong S., diZerega G.S. Accelerated recovery from irradiation injury by angiotensin peptides. Cancer Chemother Pharmacol 2002, 49:403-411.
19. Moulder J.E., Cohen E.P., Fish B.L., Hill P. Prophylaxis of bone marrow transplant nephropathy with captopril, an inhibitor of angiotensin-converting enzyme. Radiat Res 1993, 136:404-407.
20. Charrier S., Michaud A., Badaoui S., et al. Inhibition of angiotensin I-converting enzyme induces radioprotection by preserving murine hematopoietic short-term reconstituting cells. Blood 2004, 104:978-985.
21. McPherson C. Reduction of Pseudomonas aeruginosa and coliform bacteria in mouse drinking water following treatment with hydrochloric acid and chlorine. Lab Anim Care 1963, 13:737-744.
22. Davis T.A., Clarke T.K., Mog S.R., Landauer M.R. Subcutaneous administration of genistein prior to lethal irradiation supports multilineage, hematopoietic progenitor cell recovery and survival. Int J Radiat Biol 2007, 83:141-151.
23. Escribano G., Torrado D., Torrado D. Stability study of an aqueous formulation of captopril at 1 mg/ml (Spanish). Farm Hosp 2005, 29:30-36.
24. Day R., Barshishat-Kupper M., Mog S.R., et al. Genistein protects against biomarkers of delayed lung sequelae in mice surviving high dose total body irradiation. J Radiat Res 2008, 49:361-372.
25. Stickney D.R., Dowding C., Garsd A., et al. 5-androstenediol stimulates multilineage hematopoiesis in rhesus monkeys with radiation-induced myelosuppression. Int Immunopharmacol 2006, 6:1706-1713.
26. Rodgers K.E., Xiong S., Steer R., diZerega G.S. Effect of angiotensin II on hematopoietic progenitor cell proliferation. Stem Cells 2000, 18:287-294.
27. Jokubaitis V.J., Sinka L., Driessen R., et al. Angiotensin-converting enzyme (CD143) marks hematopoietic stem cells in human embryonic, fetal, and adult hematopoietic tissues. Blood 2008, 111:4055-4063.
28. Ferdinand K.C., Taylor C. The management of hypertension with angiotensin receptor blockers in special populations. Clin Cornerstone 2009, 9(SUPPL 3):S5-S17.
29. Bommer W.J. Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: part 2. Prev Cardiol 2008, 11:215-222.
30. Cheng T., Rodrigues N., Shen H., et al. Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science 2000, 287:1804-1808.
31. Glicklich D., Burris L., Urban A., et al. Angiotensin-converting enzyme inhibition induces apoptosis in erythroid precursors and affects insulin-like growth factor-1 in posttransplantation erythrocytosis. J Am Soc Nephrol 2001, 12:1958-1964.
32. van Brummelen P., Willemze R., Tan W., et al. Captopril associated agranulocytosis. Lancet 1980, 1:150.
33. Casato M., Pucillo L., Leoni M., et al. Granulocytopenia after combined therapy with interferon and angiotensin-converting enzyme inhibitors: evidence for a synergistic hematological toxicity. Am J Med 1995, 99:386-390.
34. Israeli A., Or R., Leitersdorf E. Captopril-associated transient aplastic anemia. Acta Haematol 1985, 73:106-107.
35. Gavras I., Graff L., Rose B., et al. Fatal pancytopenia associated with the use of captopril. Ann Intern Med 1981, 94:58-59.
36. Na Nakorn T., Traver D., Weissman I.L., Akashi K. Myeloerythroid-restricted progenitors are sufficient to confer radioprotection and provide the majority of day 8 CFU-S. J Clin Invest 2002, 109:1579-1585.
37. Hosseinimehr S.J., Mahmoudzadeh A., Akhlagpour S. Captopril protects mice bone marrow cells against genotoxicity induced by gamma irradiation. Cell Biochem Funct 2007, 25:389-394.
38. Chopra M., Scott N., McMurray J., et al. Captopril: a free radical scavenger. Br J Clin Pharmacol 1989, 27:396-399.
39. Williams R.N., Parsons S.L., Morris T.M., Rowlands B.J., Watson S.A. Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models. Eur J Surg Oncol 2005, 31:1042-1050.
40. Moulder J.E., Fish B.L., Cohen E.P. Treatment of radiation nephropathy with ACE inhibitors and AII type-1 and type-2 receptor antagonists. Curr Pharm Des 2007, 13:1317-1325.
41. Moulder J.E., Cohen E.P. Future strategies for mitigation and treatment of chronic radiation-induced normal tissue injury. Semin Radiat Oncol 2007, 17:141-148.
42. Ma J., Shi M., Li J., et al. Senescence-unrelated impediment of osteogenesis from Flk1+ bone marrow mesenchymal stem cells induced by total body irradiation and its contribution to long-term bone and hematopoietic injury. Haematologica 2007, 92:889-896.
43. Dominici M., Rasini V., Bussolari R., et al. Restoration and reversible expansion of the osteoblastic hematopoietic stem cell niche after marrow radioablation. Blood 2009, 114:2333-2343.
44. Zhang J., Niu C., Ye L., et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003, 425:836-841.
45. Kopp H.G., Hooper A.T., Avecilla S.T., Rafii S. Functional heterogeneity of the bone marrow vascular niche. Ann N Y Acad Sci 2009, 1176:47-54.
46. Nilsson S.K., Johnston H.M., Whitty G.A., et al. Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood 2005, 106:1232-1239.